The Truth about Teams
When it comes to team performance and adherence to “best practices,” what works…
Running the Biopharma Marathon
When I moved to Boston over thirty years ago, I had never even heard of the…
Rare Diseases: Shaping Biopharma’s Future from the Past
We just completed Rare Disease month. With that in mind, Sue has asked me to…
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness…
Spotlight on Transitions
This topic of “transition” came home to me (literally and figuratively) over the Thanksgiving holiday. With our adult kids returning, my husband and…
Networking in Biopharma: Four Ways to Build Better Relationships
Networking! You know, that activity that one either embraces or goes running away from as quickly as possible. For many, the word evokes a grueling,…
Biopharma Brand Team and Launch Team Structure: A Practical Guide
For those of you following closely (thank you!), you may recall that in an earlier e-conversation — 21st Century Commercialization — More than a…
Biopharma Governance and Decision-Making: How to Fix What’s Broken
At your next company lunch and learn, try this experiment: Ask ten people from different functions to take a blank piece of flip chart paper…
The Future of Biopharma Commercialization Strategy Is Now
Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO,…
Biopharma Launch Planning for Emerging Companies: Four Key Challenges
Living in a parallel universe, launching a company and drug simultaneously.
Tales from the Healthcare Front Lines
Each month, you have given our team permission to communicate our views on the biopharma industry, its leadership, and overall commercialization of…